# Recruitment Velocity & Enrollment Power

In operational research, does Africa's high recruitment velocity reflect genuine research efficiency or structural factors related to treatment scarcity and high disease burden? This analysis estimated enrollment rates from 23,873 African trial registrations using enrollment targets and duration estimates from ClinicalTrials.gov through March 2026. African trials showed estimated enrollment rates approximately 2.5 times faster than European trials, with the highest velocities in HIV (1,793 trials), malaria (531 trials), and tuberculosis (489 trials) research. Rapid enrollment is driven by high disease burden, treatment scarcity that makes trial participation the only source of free healthcare, and large populations within walking distance of urban trial sites. While sponsors value Africa's recruitment velocity for accelerating drug development timelines, the ethical implications of enrolling participants whose primary motivation is healthcare access remain unresolved. These findings reframe Africa's recruitment advantage as an ethical concern rather than a pure operational strength. Interpretation is limited by the estimation of enrollment rates from summary data.

## References

1. Drain PK, et al. "Global migration of clinical trials." Nat Rev Drug Discov. 2018;17:765-766.
2. Murthy S, et al. "Participation in global health research." Lancet. 2015;386:1775-1776.

## Note Block

- Type: research
- App: https://mahmood726-cyber.github.io/africa-e156-students/methods-systems/dashboards/recruitment-velocity.html
- Code: https://github.com/mahmood726-cyber/africa-e156-students/blob/master/methods-systems/code/recruitment-velocity.py
- Data: ClinicalTrials.gov API v2
- Date: 2026-04-05